Traws Pharma (NASDAQ:TRAW) Cut to “Sell” at Wall Street Zen

Traws Pharma (NASDAQ:TRAW) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other research analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Traws Pharma in a report on Monday. HC Wainwright began coverage on shares of Traws Pharma in a research note on Wednesday. They set a “buy” rating and a $8.00 target price on the stock. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.00.

Traws Pharma Stock Performance

Shares of TRAW stock opened at $2.29 on Friday. Traws Pharma has a fifty-two week low of $0.97 and a fifty-two week high of $19.44. The firm has a market capitalization of $18.30 million, a price-to-earnings ratio of 0.02 and a beta of 1.74. The stock’s 50-day simple moving average is $2.40 and its 200-day simple moving average is $1.87.

Traws Pharma (NASDAQ:TRAW) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($9.16) by $8.82. Traws Pharma had a net margin of 3,028.25% and a negative return on equity of 2,883.04%.

Hedge Funds Weigh In On Traws Pharma

Several institutional investors and hedge funds have recently bought and sold shares of TRAW. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Traws Pharma in the 1st quarter valued at approximately $759,000. Vestal Point Capital LP raised its position in shares of Traws Pharma by 133.3% during the 1st quarter. Vestal Point Capital LP now owns 175,000 shares of the company’s stock valued at $402,000 after buying an additional 100,000 shares during the period. Finally, Two Sigma Investments LP lifted its holdings in Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after acquiring an additional 5,955 shares during the last quarter. 7.95% of the stock is currently owned by institutional investors and hedge funds.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.